NEW YORK (GenomeWeb) — Discovery Life Sciences (DLS), a resident associate company of the HudsonAlpha Institute for Biotechnology, plans to acquire HudsonAlpha's Genomic Services Lab (GSL) for an undisclosed amount, the organizations said today.
Through the acquisition, DLS will form a new division called HudsonAlpha Discovery that will combine the GSL's expertise with DLS's global biospecimen and analytic services to provide clinically and scientifically annotated biospecimens, gene sequencing, bioinformatics, and laboratory services to the pharmaceutical, biotechnology, and diagnostics industries.
A spokesperson for DLS noted that the firm has acquired all of GSL's assets, technology, and staff. The new division will be located on the HudsonAlpha campus and will continue to provide services for the institute's research initiatives and external projects, HudsonAlpha said.
Shawn Levy, director of the GSL, will continue in his role as HudsonAlpha investigator and will serve as CSO for Genomics at DLS.
HudsonAlpha said that the creation of HudsonAlpha Discovery makes DLS the largest resident associate company. Over the next five years, the new division is expected to create up to 100 new job opportunities.
"We are so very proud that the institute selected Discovery to be the stewards of the Genomic Services Laboratory going forward, and of their investment in the future of our company," DLS CEO Glenn Bilawsky said in a statement.
"The HudsonAlpha Discovery platform is one of the largest global installations of the newest Illumina NovaSeq technology, which gives us the scale, speed, and quality to tackle the size and complexity of any sequencing project," Bilawsky added. "With HudsonAlpha Discovery, Discovery Life Sciences is the largest and most capable company to satisfy global market demand for a single strategic partner to provide biospecimens, pathology, immunohistochemistry, flow cytometry, sequencing, and bioinformatics services to accelerate product development."